Last reviewed · How we verify
NCT04084080: SCD-CARRE
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Phase 3 trial testing Red Blood Cell in Sickle Cell Disease in 173 participants. Participants enrolled and being followed up; not accepting new ones.
31 May 2026
Quick facts
| Lead sponsor | University of Pittsburgh |
|---|---|
| Phase | Phase 3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 173 |
| Start date | 26 February 2020 |
| Primary completion | 31 May 2026 |
| Estimated completion | 31 May 2026 |
| Sites | 23 locations across France, United States, Brazil |
Drugs / interventions tested
- Red Blood Cell — full drug profile →
- Standard of care
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sponsor
University of Pittsburgh
Who can join
18 and older, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The nephropathy of sickle cell trait and sickle cell disease.
Ataga KI, Saraf SL, Derebail VK. · · 2022 · cited 63× · PMID 35190716 · DOI 10.1038/s41581-022-00540-9 -
Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ, Kimber C, Hopewell S, Trivella M, et al · · 2020 · cited 10× · PMID 32250453 · DOI 10.1002/14651858.cd012389.pub3 -
Treatment dilemmas: strategies for priapism, chronic leg ulcer disease, and pulmonary hypertension in sickle cell disease.
Azbell RCG, Desai PC. · · 2021 · cited 8× · PMID 34889382 · DOI 10.1182/hematology.2021000275 -
Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB, Carpenter A, Dale-Harris I, Dorée C, et al · · 2023 · cited 7× · PMID 37539955 · DOI 10.1002/14651858.cd012380.pub3 -
Management of Older Adults with Sickle Cell Disease: Considerations for Current and Emerging Therapies.
Oyedeji CI, Hodulik KL, Telen MJ, Strouse JJ. · · 2023 · cited 7× · PMID 36853587 · DOI 10.1007/s40266-023-01014-8 -
Transfusion therapy for sickle cell disease: what's new?
Chou ST, Hendrickson JE, Fasano RM. · · 2023 · cited 3× · PMID 36562748 · DOI 10.1182/bloodadvances.2022009283 -
Natural History of Chronic Kidney Disease in Sickle Cell Disease.
Ataga KI. · · 2026 · PMID 41927315 · DOI 10.1002/ajh.70300 -
The right patient, the right treatment: tailoring sickle cell disease care.
Alan S, Desai P. · · 2025 · PMID 41348034 · DOI 10.1182/hematology.2025000753
Verify or expand the search:
- PubMed search for NCT04084080
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Red Blood Cell
Trials testing the same drug.
- NCT03999229 — S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion · Phase 1 · recruiting
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other University of Pittsburgh trials
Trials by the same sponsor.
- NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
- NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
- NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
- NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
- NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04084080 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
- Last refreshed: 4 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04084080.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing